Theses›Healthcare & bio›Organoid safety testing

Organoid safety testing

Organoid safety testing: human tissue replacing the animal toxicity study

  • Bear
  • Early
  • $3.5B by 2035

The callRestraints win for now: regulators have opened the door, but the buyers still pay for animal studies and the contract labs that sell them are best placed to sell the replacement.

D1D2R1R2R3C1C2foragainst D1D2R1R2R3C1C2foragainst
Fig. 1The balance. Drivers and catalysts against restraints, each block sized by its weight; catalysts hang dashed because they have not happened yet, sized by their odds. It tips toward the restraints.
  1. D1FDA's antibody guidance (Dec 2025) cuts the routine six-month monkey study, and its March 2026 draft guidance sets out how a non-animal method gets accepted.
  2. D2The EU's June 2026 roadmap covers chemical safety in 15 domains, opening cosmetics, chemicals, pesticides and veterinary buyers, though its targets are indicative.
  3. R1The spend has not moved: Charles River's safety work grew on monkey-study demand in Q3 2026 and its CEO calls non-animal control groups revenue-neutral.
  4. R2Organoids vary batch to batch, so a method cannot yet be validated once and trusted everywhere the way an animal study is.
  5. R3The CROs own the sponsor relationships and the regulated labs, so they can buy the winners and sell the data as a service.
  6. C1A drug sponsor or the FDA confirms a filing where organoid or organ-chip data replaced a six-month monkey study.end-2027
  7. C2An organoid or organ-chip method is listed in FDA's database of accepted non-animal methods for a safety use.mid-2027
What would prove itdated tests, open and resolved
202720282029today12345predictionswatch 202720282029today12345predictionswatch
Fig. 2Each ring is a dated test: dashed while open, struck through when overdue, ticked or crossed once resolved.
  1. 1By 30 Jun 2027 a company selling organoid or organ-chip safety testing raises a single round of $50M or more.Jun 2027 · open
  2. 2By 31 Dec 2027 a drug sponsor or the FDA publicly confirms an IND or BLA accepted with human organoid or organ-chip data standing in for a 6-month non-human primate toxicity study.Dec 2027 · open
  3. 3Charles River's Safety Assessment business grows organically in calendar 2027: the animal study is not yet being displaced fast enough to show in the largest CRO's numbers.Mar 2028 · open
  4. 4By 31 Dec 2028 a listed CRO acquires an organoid or organ-chip company for $100M or more.Dec 2028 · open
  5. 5Charles River's 2027 safety assessment growth: still positive means the animal study is not yet being displaced.Dec 2028 · open
Expressionslisted, private, technologies
  • NYSE: CRLCharles River Laboratories
    • not screened
     Preclinical safety (toxicology) studies including non-human primate studies, plus a growing non-animal methods line.
Private · 26 private companies, 5 of them in Switzerland.

DNTOX · FluoSphera · Cellbox Labs · mo:re · Visienco · The Organoid Company · StemX Bio · Syntopia · Lucero · 60Nd · OrganAID · VitrofluidiX · SBMatrices · Foresee Biosystems · Myomaker Bio · VivoSphere UK · Sansanima · Finnadvance · Newcells Biotech · Cellesce · MaxWell Biosystems · 3Brain · Phasics · Vivodyne · InSphero · Parallel Bio

2 more private companies tracked, not shown

Technologies
Who has already bet on itprivate rounds, from public sources

$70M raised by 6 companies, $68M of it in the last three years. Wave building: Money is arriving: recent rounds, but no runaway leader yet.

  • $40MVivodyne Series A, May 2025 $40M
  • $21MParallel Bio Series A, Jun 2025 $21M
  • $5MCellbox Labs
    • Founded 2020
     Round, 2025 $4M · Pre-Seed, 2024 $1M
  • $3Mmo:re
    • Founded 2023
     Seed, Mar 2025 $3M
  • $2MDNTOX
    • Founded 2022
     Seed, Jun 2023 $2M
  • ·The Organoid Company
    • Founded 2025
     Rounds not itemised
What changedthe record, newest first
  • 5 Nov 2026Regulators have cut animal testing requirements, but the biggest animal-testing lab grew its safety business last quarter. The rules moved before the money did.
  • 5 Nov 2026Toxicity testing is already bought as its own line item, so organoids do not have to replace a clinical trial to find a buyer; they have to replace the animal study.
  • 4 Nov 2026People who have grown organoids say the hard part is getting the same tissue twice.